What Role Do Atypical Antipsychotic Drugs Have in Treatment-Resistant Depression?
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Despite significant advances in the treatment of depression, many patients fail to respond to treatment with adequate dose and duration. Multiple therapeutic approaches are available for the treatment of patients not responding to standard antidepressant medication. These include switching medication or combination and augmentation strategies. A substantial number of patients do not respond to multiple treatment trials. These patients suffer from treatment-resistant depression (TRD) and represent a challenge to the treating physician. There have been a growing number of reports on the use of atypical antipsychotics as augmenting agents in nonpsychotic TRD. Second-generation antipsychotics are less likely to provoke parkinsonian side effects. It has also been reported that these agents produce lower rates of tardive movement disorders than traditional neuroleptics. Furthermore, second-generation antipsychotics are serotonin-2A/2C antagonists, possibly allowing them to improve the efficacy and some aspects of the side effect profile of selective serotonin reuptake inhibitors (SSRIs). Weight gain and sedation are likely to be the most common adverse events of such combined therapy. In a recent controlled clinical trial, the atypical antipsychotic olanzapine was combined with fluoxetine therapy in an 8-week, double-blind clinical trial in patients with TRD. This combination drug therapy demonstrated clinical efficacy on several rating scales and showed rapid onset of action. Although more studies will be required to confirm and extend these findings, the results suggest that there may be a clinical benefit to combining atypical antipsychotics with SSRIs in nonpsychotic TRD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Risperidone Augmentation of Selective Serotonin Reuptake Inhibitors in Major Depression
Ostroff, R. B., & Nelson, J. C. (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0410 · Cited by 248
Rush, A. J., Armitage, R., Gillin, J. C., Yonkers, K. A., Winokur, A., Moldofsky, H., Vogel, G. W., Kaplita, S. B., Fleming, J. B., Montplaisir, J., et al. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00092-4 · Cited by 215
Cited by
Serotonin receptors : their key role in drugs to treat schizophrenia
Meltzer, H. Y., Li, Z., Kaneda, Y., & Ichikawa, J. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2003.09.010 · Cited by 775
Bauer, M., Pfennig, A., Severus, E., Whybrow, P. C., Angst, J., Möller, H.-J., & Šon behalf of the Task Force on Unipolar Depressive Disorders (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2013.804195 · Cited by 632
“…better response rate to the combination of an antidepressant plus an antipsychotic than to treatment with either component alone (Spiker et al. 1985; Rothschild et al. 1993; Bruijn et al. 2001; Thase 2002; Rothschild 2003; Shelton 2003; Klein et al. 2004; Kunzel et al. 2009; Wijkstra et al. 2010).”
BackgroundBDNF in schizophrenia, depression and corresponding animal models
Angelucci, F., Brenè, S., & Mathé, A. A. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001637 · Cited by 548
Bauer, M., Bschor, T., Pfennig, A., Whybrow, P. C., Angst, J., Versiani, M., Möller, H.-J., WFSBP Task Force on Unipolar Depres, Bauer, M., Bschor, T., et al. (2007) · The World Journal of Biological Psychiatry · doi:10.1080/15622970701227829 · Cited by 477
The comorbidity of insomnia, chronic pain, and depression: Dopamine as a putative mechanism
Finan, P. H., & Smith, M. T. (2013) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2012.03.003 · Cited by 363
Metadata
- Authors
- Thase, M. E.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2002-02-15
- Volume
- 63
- Issue
- 2
- Pages
- 95-103
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2029066588
- Cited by
- 108
- References
- 2
- FWCI
- 8.39
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: What Role Do Atypical Antipsychotic Drugs Have in Treatment-Resistant Depression? https://app.cochat.ai/papers/10.4088/jcp.v63n0202
- The paper
- Thase, M. E. (2002). What Role Do Atypical Antipsychotic Drugs Have in Treatment-Resistant Depression? The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.v63n0202
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.